Skip to main navigation
Oyster Point Pharma Oyster Point Pharma Oyster Point Pharma Oyster Point Pharma

Investor Relations

  • Who We Are
    • Board of Directors
    • Leadership Team
  • Our Focus
  • Pipeline
    • OC-01
  • Investors & News
    • News & Events
      • News Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Investor Requests
      • Email Alerts
  • Careers
  • Contact
Oyster Point Pharma Oyster Point Pharma

Investor Relations

  • Who We Are
    • Board of Directors
    • Leadership Team
  • Our Focus
  • Pipeline
    • OC-01
  • Investors & News
    • News & Events
      • News Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Investor Requests
      • Email Alerts
  • Careers
  • Contact

Breadcrumb

  1. Home
  2. Investors
  3. Node

Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

  • Read more about Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

  • Read more about Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

  • Read more about Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

  • Read more about Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

  • Read more about Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

  • Read more about Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

  • Read more about Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

  • Read more about Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

  • Read more about Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

  • Read more about Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next page Next ›
  • Last page Last »
Subscribe to

Shareholder Tool

Print Page
Email Alerts
Information Requests
logo

Investor Relations

  • Who We Are
  • Our Focus
  • Pipeline
  • Investors & News
  • Careers
  • Contact

Footer Menu Two

  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Sitemap

Oyster Point Pharma, Inc
202 Carnegie Center, Suite 109
Princeton, New Jersey 08540
United States

General Inquiries
(609) 382-9032
info@oysterpointrx.com

Media Contact
media@oysterpointrx.com

© 2021 Oyster Point Pharma, Inc. Oyster Point™ and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.

Social Menu

We use cookies to deliver our online services. Details of the cookies can be found by clicking the 'Cookie settings' link. To agree to our use of cookies click 'Accept.'. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. The cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. The cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.